From 2007 to 2016, there was an increase in the proportion of substance use treatment facilities offering medication treatment.
Investigators examined whether adolescents who use marijuana heavily develop acute psychotic symptoms at a much higher rate than youths who use marijuana minimally or not at all.
A set of characteristics of nonmedical use of prescription opioids in adolescents may help identify youth at high risk for substance use disorder, including opioid misuse, in early midlife.
Patients with chronic pain and a history of physical and sexual abuse were found to be more likely to concurrently use benzodiazepine and opioids.
The investigational fatty acid amide hydrolase inhibitor PF-04457845 may decrease cannabis withdrawal symptoms and dependence in men.
Alprazolam was found to be the most commonly misused benzodiazepine.
The use of telemedicine for substance use disorder is relatively low in a commercially insured population.
Warning letters about products illegally marketed as treatments for opioid addiction, pain, and anxiety have been sent to 2 companies, the FDA said Tuesday.
Sandoz and Pear Therapeutics announced the availability of reSET, the first prescription digital therapeutic for patients with substance use disorder.
Two studies indicate a link between cannabis use and mental health concerns, starting in adolescence and continuing into adulthood.